Search - tctmd.com

Displaying 361 - 380 of 628

Sort: Relevancy | Date

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prehospital or Crushed Ticagrelor!

Presenter: Eric Boersma, E. Magnus Ohman, Dimitrios Alexopoulos

October 12, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo

October 11, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Presenter: C. Michael Gibson, Marco Valgimigli, Guido Parodi

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Daily News

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

Yael L. Maxwell

October 09, 2015

News Daily News

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Yael L. Maxwell

October 09, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Caitlin E. Cox

October 06, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

News Daily News

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

L.A. McKeown

September 21, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Conference News ESC 2015

Prehospital Administration of Ticagrelor Cuts Early Ischemic Events in STEMI Patients

L.A. McKeown

September 01, 2015

News Conference News ESC 2015

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Yael L. Maxwell

August 31, 2015

News Daily News

Un Estudio de Registro Sugiere que AVB y SLF son Iguales en Pacientes Diabéticos No Seleccionados

August 27, 2015

News Daily News

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

August 27, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

替卡格雷预治疗有助于预防 NSTE-ACS 围手术期心肌坏死

June 04, 2015

Advertisement

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prehospital or Crushed Ticagrelor!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

Prehospital Administration of Ticagrelor Cuts Early Ischemic Events in STEMI Patients

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Un Estudio de Registro Sugiere que AVB y SLF son Iguales en Pacientes Diabéticos No Seleccionados

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

替卡格雷预治疗有助于预防 NSTE-ACS 围手术期心肌坏死

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content